Telisotuzumab Biosimilar - Research Grade

Human

MET

5mg/ml

Human IgG1 (K214R//K222Del/T223C/225Del)-kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P08581

Blue ice

MET (the HGF receptor) is a receptor tyrosine kinase that drives proliferation, motility, and survival signalling and is a frequently studied oncogenic target. Offered as an unconjugated, non-therapeutic analog of telisotuzumab, this research-grade anti-human MET recombinant monoclonal antibody is intended for research use only (RUO). It is manufactured to demanding in vivo standards, formulated for low endotoxin, and supplied in scalable milligram (mg) to gram (g) quantities for high-throughput and heavy-usage laboratories. Typical uses include receptor-signalling assays, in vitro screening, ADC development, and in vivo oncology models requiring a reproducible reagent.

ABT-700,hz224G11;met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2

Detects human MET

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.